16–17 September 2026 · Barcelona
The first conference for industry Value-Added Medicines and 505(b)(2). From early ideation to market — under one roof.
Organised by Annion Pharma
There is no industry-run, end-to-end, US ↔ EU conference dedicated to Value-Added Medicines and 505(b)(2). HYBRIDGE owns that white space.
End-to-end scope
Ideation, IP, non-clinical, clinical, regulatory (US + EU), market access, BD and licensing — all in two days.
Industry voices
Operators from Bluepharma, Polpharma, Adalvo, Nanomol, Galenicap, Valdiano — not vendor sales decks.
A working network
Intentionally intimate (~50 attendees), no exhibition-hall noise — every conversation matters.
Day 1 · Training
Wed 16 SepDay 2 · Industry experience
Thu 17 SepAna Gavaldá
AnnionAna Caterina Pinto
BluepharmaRosanne d'Alessio
ValdianoNicolay Ferrari
ArendiBio SolutionsCarlos Rodriguez
PolpharmaJames Burt
ProductLifeHans Platteeuw
Galenicap / NeuraxpharmToni Santamaria
AdalvoIrene Casalprim
AdalvoWhy attend
Two days end-to-end, designed so you walk out with a working playbook and the network to execute it — not a folder of slide decks you'll never re-open.
Two days mapped end-to-end: ideation, IP, non-clinical, clinical, regulatory (US + EU), market access, BD and licensing — finally in one place.
Operators from Bluepharma, Polpharma, Adalvo, Nanomol, Galenicap and Valdiano share what actually worked — and what they would have done differently.
Dual regulatory and clinical perspective from speakers active in both markets. Saves you the budget and time of attending two separate conferences.
Intentionally intimate — ~50 senior attendees, no exhibition-hall noise. The people you meet on day 1 are the ones you call when you hit a roadblock six months later.
Round-table sessions on which 505(b)(2) assets are worth pursuing — with the executives who make those calls for a living.
What investors, licensors and acquirers actually look for — directly from those who package, pitch and value these programmes.
Made for portfolio leads, regulatory affairs, business development and R&D heads working on Value-Added Medicines and 505(b)(2) programmes.
Venue
Hosted in the centre of Barcelona — a pharma cluster with strong connections to both EU and US markets. The evening networking event is the moment most attendees remember a year later.
FAQ
Quick answers to the most common questions. Don't see yours? Get in touch .
16–17 September 2026, in Barcelona. Venue announced to confirmed attendees one month before the event.
Mid-to-senior professionals in pharma working on Value-Added Medicines and 505(b)(2) — portfolio leads, regulatory affairs, business development, R&D heads, market access, and CDMOs supporting these programmes.
Yes — all sessions, materials and round-table discussions are in English.
Access to all sessions across both days, lunch and coffee breaks, the evening networking event on 16 September, and the full programme materials.
Register two or more delegates from the same company in one submission and the per-seat price drops automatically to €1,530 (15% off the standard rate). No code needed.
Early-bird pricing (€1,620 / 10% off) is available until 30 July 2026. After that, single tickets are €1,800.
Yes. Free substitution up to 7 days before the event. Refunds are available more than 50 days out (admin fee applies); after that you can transfer to next year. Full schedule in our cancellation policy — it sits alongside our terms of use.
After you submit the registration form we email you a secure Revolut payment link. Pay with card, Apple Pay, Google Pay or Revolut Pay — from any device. Your seat is confirmed as soon as payment clears, and we send a VAT receipt for your accounting.
Early bird
€1,620
10% off · before 30 Jul
Standard
€1,800
Single delegate
2+ delegates
€1,530
15% off · per seat
All tiers include lunch, coffee breaks and the networking event.
Founding sponsors get unmatched visibility with the buying committee on both sides of the Atlantic. Three tiers — Supporting, Industry and Strategic Partner — each designed for a different commercial goal.
Founding sponsors
The VAMs Briefing
One regulatory or market signal · one operator story · one numbers panel. Unsubscribe anytime.
We come back within one business day.
